Related by context. All words. (Click for frequent words.) 71 pulmonology portfolio 69 VEGFR2 inhibitor 68 recurrent metastatic ovarian cancer 68 pralatrexate injection folate analogue 67 FOLOTYN ® 67 AAG geldanamycin analog 67 INSPIRE Trial Phase III 67 targeted radiotherapeutic 67 modified glutathione analog 65 Phase Ib clinical trials 65 vitreoretinal disorders 65 evaluating Actimmune 65 CDK cyclin dependent 65 XL# anticancer compounds 65 omecamtiv mecarbil formerly 65 IMPDH inhibitor 65 toenail onychomycosis 64 6 sulfatase 64 Homspera TM 64 CYT# potent vascular disrupting 64 evaluating picoplatin 64 developing Bicifadine serotonin 64 R Saizen R 64 neuropathic pain spasticity 64 sorafenib tablets 64 systemic RNAi therapeutic 64 ALTROPANE R 64 Selzentry Celsentri 64 lintuzumab SGN 64 HCl PEPCID ® famotidine 64 Epothilone D 64 individualized cellular immunotherapy 64 R roscovitine CDK cyclin 63 induced mucositis 63 MKC# MKC# PP 63 THE WINDS WILL 63 class mGluR5 inhibitor 63 phenylalanine ammonia lyase 63 humanized therapeutic 63 personalized cellular immunotherapy 63 IMiDs R 63 Viprovex R 63 NU# direct 63 dihydrochloride Tablets 63 oral prodrug 63 topically applied SEPA 63 ACTUAL RESULTS COULD DIFFER 63 MKC# MT 63 CYP#A# CYP#D# 63 PNP inhibitor 63 candidate XP# 63 HCV NS5B polymerase 63 oncolytic virus therapies 63 IMA# 63 dependent kinase inhibitor 63 Frozen Shoulder syndrome Adhesive 63 cosmetic cosmeceutical products 62 Crofelemer budesonide foam 62 triggers apoptosis programmed 62 PEG PAL PEGylated recombinant 62 refractory chronic lymphocytic 62 XP# XP# 62 forodesine purine nucleoside phosphorylase 62 renin inhibition promising 62 Intermezzo ® zolpidem tartrate 62 THAT ARE DIFFICULT TO 62 investigational oral inhibitor 62 Agonist MABA program 62 oral proteasome inhibitor 62 PURPOSE OF SAFE HARBOR 62 interferon gamma 1b 62 DATE HEREOF AND 62 HuCAL PLATINUM ® CysDisplay 62 pharmacogenomic translational research 62 pan histone deacetylase 62 Ovitrelle R Serostim 62 includes TOLAMBA TM 62 Exelixis compounds 62 YOUR LOCAL ANIMAL SHELTER 62 GALNS N acetylgalactosamine 62 inflammatory autoimmune diseases 62 kidney urologic 62 investigational humanized monoclonal antibody 62 ATRA IV 62 Vitrasert R 62 anti botulism antibody 62 TNF Tumor Necrosis Factor 62 Pruvel TM 62 overactive bladder AA# 62 MKC# 62 Telik logo TELINTRA 62 Romidepsin 62 Cetrorelix 61 REPORTS FILED FROM 61 STOP SHOPPING FOR 61 virus HCV protease inhibitor 61 Daclizumab 61 multi kinase inhibitor 61 phase IIb clinical 61 AND TO REOFFER 61 Isis# where 61 intravesical infusion therapy 61 rheumatoid arthritis thrombocytopenia 61 FOLFOX6 chemotherapy regimen 61 novel VDA molecule 61 IMiDs ® 61 THAT SPEAK AS 61 liposomal formulation 61 candidates Azedra TM 61 dasatinib Sprycel ® 61 CYP#A# isoenzyme 61 Solazed TM 61 Panzem R 61 malignant mesothelioma Alfacell 61 brand ciclesonide HFA 61 delivers fluocinolone acetonide FA 61 USP Tablets PEPCID 61 HYVISC ® treatment 61 Pruvel ™ 61 HepeX B TM 61 DG# compounds targeting 61 oral ridaforolimus 61 Combivir Kivexa 61 WHICH ARE NOT PURELY 61 ALN PCS 61 interferon beta 1a infertility 61 certain protein tyrosine 61 clinical trials Archexin 61 AAG KOS 61 ANY SHARES 61 orally administered inhibitor 61 TO BE FOUND 61 hypoxia activated prodrug 61 essential thrombocythemia ET 61 ELADUR ™ 61 ragweed allergy immunotherapeutic 61 acyclovir Lauriad R 61 Pirfenidone 61 THR beta agonist 61 CINQUIL 61 sapacitabine CYC# 61 IMiDs 61 SinuNase TM 61 mGluR5 negative 61 arthritis PsA 60 MEK Inhibitor 60 rheumatoid arthritis psoriatic arthritis 60 leading oral taxane 60 allosteric modulator PAM 60 MAGE A3 ASCI 60 MATTERS DISCUSSED IN 60 docetaxel Taxotere R 60 candidate REP# 60 evaluating intravenous picoplatin 60 PLAN OR EXPECT 60 sodium Injection 60 Bezielle 60 www.ucb group.com 60 CEL SCI Phase III 60 CHASE DRIVERS 60 Zenvia ™ 60 infectious diseases autoimmune diseases 60 WEBSITE ONCE IT 60 HGS ETR1 mapatumumab 60 IAP inhibitor 60 2 methoxyestradiol 60 erlotinib Tarceva ® 60 Phase #b/#a clinical 60 recombinant PSMA vaccine 60 Potassium Chloride Sodium Ascorbate 60 investigational monoclonal antibody 60 diarrhea predominant irritable 60 LymphoStat B belimumab 60 SPEAR Study 60 Locteron ® 60 THE AUCTIONEER RESERVES 60 Personalized Immunotherapy 60 StromaCel Inc. 60 INDIVIDUALS WHO 60 INTENDED TO 60 Frederic Chabert 60 THE BASIC MATERIALS 60 RISKS UNCERTAINTIES AND ASSUMPTIONS 60 polyneuropathy HIV DSP 60 Oral Solution VISICOL 60 product platforms AZX# 60 PLEASE ONLY CLICK 60 developing Surfactant Replacement 60 THE MERGER CAREFULLY AND 60 WITHDRAW ANY ITEM 60 PDX pralatrexate 60 Sapacitabine 60 Acute Exacerbations 60 Aztreonam lysine 60 Complicated Skin 60 phenylketonuria PKU developed 60 antiangiogenesis therapies 60 prostones 60 Phase 2b Clinical Trial 60 transthyretin mediated amyloidosis ATTR 60 nephropathic cystinosis cystinosis 60 validated biomarker 60 THESE STATEMENTS ARE MADE 60 Completes Patient Enrollment 60 INVOLVING THE 60 OR REVISE ANY FORWARD 60 THESE MATERIALS AS THEY 60 OMP #R# 60 THAT ARE SUBJECT TO 60 metastatic colorectal carcinoma 60 vapreotide acetate 60 TELINTRA 60 BREAKING NEWS INVESTIGATIONS 60 next generation URAT1 60 Combination REOLYSIN R 60 Array BioPharma Reports 60 Zemiva TM 60 5 FU leucovorin 60 Namenda Memantine HCl 60 D aspartate NMDA receptor 60 evaluating tivozanib 60 ACCORDINGLY NO ASSURANCES CAN 60 Halozyme Ultrafast Insulin 60 dermatology therapies 60 generation purine nucleoside 60 novel topoisomerase 60 Immunotherapeutic 60 Xcytrin R 60 advanced metastatic renal 60 DNA RNA Medicines 60 alvespimycin 60 Oragens TM 60 REJECT ANY BID 60 TRANSDUR ® 60 THAT YOU GUYS 59 NASH Huntington 59 Phase 2a Clinical Trial 59 PEG SN# 59 THEIR ENTIRE INVESTMENT 59 tranquilizers diazepam 59 catheter occlusion 59 Vandetanib 59 autoimmune diseases inflammatory 59 IMPLIED WARRANTIES OR REPRESENTATIONS 59 oral isoform selective HDAC 59 CR# vcMMAE 59 trial evaluating PRX# 59 delta opioid receptor 59 receiving chemoradiation therapy 59 IN UNDERWRITING AGREEMENTS 59 allosteric modulator NAM 59 Elotuzumab 59 SUBSTANTIAL SHELTER 59 Iluvien ® 59 RCW Breast Cancer 59 AND EVENTUALLY 59 d l leucovorin 59 including eniluracil ADH 59 First Patient Enrolled 59 Tumour Vascular Disrupting Agent 59 BENLYSTA TM 59 Belimumab 59 CK # novel 59 AND ORAL STATEMENTS MADE 59 AS ESTIMATE ANTICIPATE BELIEVE 59 oral nucleoside analogue 59 4SC AG ISIN DE# 59 HCD# [002] 59 UNCERTAINTIES OR OTHER FACTORS 59 ADVANCE ILLUMINATE 59 WHATSOEVER WITH RESPECT TO 59 undergoing elective percutaneous 59 OFFER FREE 59 YONDELIS 59 HISTORICAL ARE FORWARD LOOKING 59 methylnaltrexone bromide 59 Peginterferon alfa 2b 59 number NCT# ClinicalTrials.gov 59 R famotidine 59 Pivotal Phase 59 forodesine 59 OR ACHIEVEMENTS IMPLIED 59 OF BAHRAINS 59 gastroenterology neurology 59 Company TAIFUN R 59 SAFE HARBOR PROVISIONS OF 59 CD#.# DOES NOT ENDORSE 59 serine protease inhibitor CU# 59 EXCHANGE OR 59 motesanib 59 Mg Usa 59 Donating CINOD class 59 DEBT AND IDENTITY 59 PROVISIONS OF THE PRIVATE 59 WHY ACTUAL RESULTS COULD 59 worsening thrombocytopenia 59 PROBE AFTER 59 ENTIRETY IF AND 59 #-MILLION DOLLARS [001] 59 erythematosus 59 cladribine Cladribine Tablets 59 'S EFFORTS TO 59 commercializing dermatological products 59 treat opioid induced 59 Seliciclib CYC# 59 Initiates Phase II 59 candidate AQ4N 59 SPL# Gel vaginal microbicide 59 CENTRAL BAHAMAS 59 NEBIDO VANTAS SUPPRELIN LA 59 Alzheimer disease cognitive impairment 59 Panzem R NCD 59 motexafin gadolinium Injection 59 Prodarsan R 59 VERIFICATION OF THE 59 Markets Commentator 59 registrational trial 59 novel orally inhaled 59 accumulate preferentially 59 SOLICITATION WILL PROVIDE COPIES 59 Selective Electrochemical Tumor Ablation 59 TRANSDUR ™ 59 Patented SDC 59 IL# PE#QQR 59 Glufosfamide 59 monoclonal antibody IgG1 Mab 59 non constipating irritable 59 NEWS RELEASE THE COMPANY 59 Dose Limiting Toxicity DLT 59 ALN TTR# 59 NORDEX EXPLOSIVES LTD 59 myelodysplastic myeloproliferative diseases 59 GVAX ® 59 SENOMYX ANNOUNCES 59 JZP 59 THE OFFER DOCUMENTS 59 CONTINUED ACCEPTANCE OF 59 Kit CD# positive 59 ROADWAYS WILL 59 molecular imaging radiopharmaceutical 59 ACCORDINGLY READERS SHOULD NOT 59 BCG refractory carcinoma 59 solid tumors ZYBRESTAT 59 skeletal muscle weakness 59 dimebon latrepirdine 59 TRADING ACT 59 Golimumab 59 Phase IIb Trial 59 AND ARE SUBJECT 59 platforms GVAX 59 hypertrichosis occurred 59 PEGylated Fab fragment 59 PUBLISHED RATINGS CRITERIA AND 59 FDA APPROVES 59 INFORMATION EXPRESS 59 antibody MAb 59 migraine headaches neuropathic pain 59 STRATEGY TO 59 ® chorionic gonadotropin 59 STATEMENT CAREFULLY WHEN 59 pseudobulbar affect PBA 59 MY PRAYERS ARE 59 evaluating satraplatin 59 GRNOPC1 contains 59 IS AVAILABLE LIE FLAT 59 OR NATURE 59 LOOKING STATEMENTS MADE PURSUANT 59 pentadentate logo R 59 MATERIALLY FROM ANY FUTURE 59 known dihydropyrimidine dehydrogenase 59 SO THEY 'RE 59 ANTICIPATES TARGETS GOALS PROJECTS 59 pirate steve video 59 inflammatory PDE 59 WHEN YOU WERE DOWN 59 THOSE DESCRIBED IN 59 evaluating carfilzomib 59 GTC recombinant human 59 INCLUDE ANY STATEMENTS REGARDING 59 BY CHRIS GIVENS 59 developing Surfactant Therapies 59 BECAUSE THIS 59 Microplasmin 59 TELINTRA R 59 HISTORICAL INFORMATION PRESENTED HEREIN 59 herpetic keratitis 59 Abiraterone acetate 59 Oral Solution OSMOPREP 59 Offering Pilates 59 ® SHOWTIME WOMEN 59 novel immunotherapies 59 Liprotamase 59 BY REPRESENTATIVES OF 59 CONCERN IS 59 Luramist TM 58 AN# topical anti 58 PROGRAM THAT 58 bevacizumab Avastin ® 58 ARE MADE AS 58 somatropin Kuvan R 58 By JENNIFER LEARN 58 MANAGEMENT 'S CURRENT BELIEFS 58 PRICED -Harllee Stadium 58 oral Janus kinase 58 DIFICID ™ 58 TO GUARANTEE 58 renal failure interstitial lung 58 aflibercept VEGF Trap 58 ALN HPN 58 Kosan dependence 58 oral picoplatin 58 C1 INH deficiency 58 SOUTHERN ERIE 58 XL# XL# XL# XL# 58 TO AVOID PREGNANCY WHILE 58 THe ORIGINAL CREDITOR WITHIN 58 Surfactant Replacement Therapies SRT 58 cell carcinoma RCC 58 THIS EMAIL AND 58 Through Glycoscience R 58 Guidelines Commenting 58 P#X# antagonist 58 OTHER THAN PURELY HISTORICAL 58 CG# oncolytic virus 58 corticotropin injection 58 R bortezomib 58 Archexin 58 EOquin TM phase 58 ENTIRETY WHEN THEY BECOME 58 Altera Nebulizer System 58 CD4 monoclonal antibody 58 lenalidomide Revlimid R 58 THE PRECIPITATION WILL 58 tanespimycin 58 By JAMAAL ABDUL 58 Aflibercept 58 thrombin component 58 vaccines oncolytic virus 58 Picoplatin Efficacy After 58 Phase III PREGNANT PROCHIEVE 58 CysDisplay R 58 PRODUCING DAMAGING WINDS IN 58 PINNACLEDIGEST.COM S PAST PERFORMANCE 58 Initiates Enrollment 58 metastatic ocular 58 THE STATEMENTS WHICH 58 sarcoma melanoma 58 ARE SUBJECT TO 58 CAN YOU COMPARE 58 THIS SITE AT 58 investigational therapies 58 OR CHANGES 58 THESE STATEMENTS FOR REVISIONS 58 THAT EVERYONE 58 TO MID #S 58 trademarks Vitrasert R 58 systemic anaplastic large 58 QUADRAMET R 58 Meets Primary Endpoint 58 THAT WE HAVE 58 oral ghrelin agonist 58 ON SCHEDULE TO 58 5 fluorouracil leucovorin 58 Pharmaceutica Ltd. 58 CONTAIN FORWARD LOOKING STATEMENTS 58 MT# MEDI 58 Tesetaxel 58 GUYS LIKE 58 AND ECONOMIC 58 EOD data 58 TO IDENTIFY SUCH FORWARD 58 CHANGES IN LOCAL GOVERNMENT 58 & BROKERAGE INDUSTRY 58 Cannabinor 58 TNFerade ™ 58 OTHER RELEVANT MATERIALS FILED 58 AZERBAIJAN HIS EXCELLENCY MR 58 oral dual endothelin 58 evaluating T DM1 58 novel antimitotic agent 58 rheumatoid arthritis psoriasis 58 developing Zerenex TM 58 ThermoDox ® clinical 58 Dementia Related Psychosis 58 Second Pivotal Phase 58 Additionally Soligenix 58 targeted immunotherapies 58 Note SHIPPING CHARGES 58 BY KEVIN KELLY 58 mecarbil 58 COMIC REEL WRAP 58 PRESENTED AT 58 WISE LEADERSHIP OF 58 BEMA ® 58 CAUTIONARY STATEMENT UNDER 58 chronic myeloid 58 damage cirrhosis liver 58 oncolytic viruses 58 Trofex 58 Intravenous palifosfamide 58 hepatitis C lupus 58 READERS SHOULD NOT 58 IMC #B 58 Randomized Double blind 58 drug pipeline TAFA# 58 INTENDS PLANS BELIEVES SEEKS 58 nilotinib Tasigna ® 58 opioid induced bowel dysfunction 58 rALLy clinical trial 58 Safinamide 58 TO DETECT 58 #-THOUSAND DOLLARS [001] 58 cutaneous T 58 THEY SAY THE 58 Retorted Huckabee 58 cardiac myosin activator omecamtiv 58 NicVAX TM 58 MyVax R 58 OR ASSIGNS MAY BE 58 RELOVAIR ™ 58 By Lisa Eckelbecker 58 ALN VSP 58 PEGylated docetaxel 58 use transdermal sumatriptan 58 receptor tyrosine kinase inhibitor 58 ENTERTAINMENT ANNOUNCES 58 fluoroquinolone class 58 NVA# 58 Therapies SRT 58 Endologix Powerlink System 58 MADE OR TO REFLECT 58 INFORMATION TECHNOLOGY EQUIPMENT 58 Acetavance TM intravenous acetaminophen 58 AND RELATED MATERIALS BECAUSE 58 cetuximab Erbitux R 58 THE BENEFIT OF HINDSIGHT 58 Synta Announces 58 WEB SITE OR 58 ALN TTR 58 small molecule glucokinase 58 Semicondtr 58 PLEASE NOTE Commenting 58 venous thrombosis indications 58 candidate Zemiva 58 Inc. AMEX YMI 58 INTENTIONS REGARDING THE FUTURE 58 CTA# Injection 58 IS NOT AFFECTED BY 58 Entereg R 58 FEMALES SHOULD BE ADVISED 58 ® lenalidomide 58 velafermin 58 Alfacell proprietary ribonuclease 58 influenza BCX# purine nucleoside 58 LEVEL OF SUPPORT FOR 58 Amgen Neulasta R 58 EnteroMedics proprietary neuroblocking technology 58 Health RxList theHeart.org 58 alpha folate receptor 58 oral calcitonin licensed 58 humanized interleukin 6 58 myocardial infarction ventricular fibrillation 58 Staccato loxapine 58 PEGylated interferon beta 1a 58 asthma COPD Chronic 58 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 58 registrational 58 de novo kidney transplant 58 PUBLIC WEBSITE WWW.FITCHRATINGS.COM 58 TO REDUCE THE 58 Nicotine Conjugate Vaccine 58 OR REFLECT THE 58 Quinamed 58 commercializing oxidized glutathione 58 mocetinostat MGCD# 58 acute peptic ulcer 58 Solzira TM 58 WEATHER INFORMATION 58 Diabetic Macular Edema DME 58 non thiazolidinedione TZD 58 DOUBTS WE PREFER THAT 58 hormone LHRH antagonist 58 SIMILAR EXPRESSIONS ARE INTENDED 57 Squibb Genentech 57 compound PMX # 57 INFORMATION AS 57 R#/MEM # 57 biodefense pathogens 57 orBec ® oral beclomethasone 57 nephropathic cystinosis 57 interferon alpha IFN 57 Sie lesen Finanznachrichten und 57 antibody MT# 57 Empatic ™ 57 IS EXPECTED TO OCCUR 57 QUINTE HEALTH CARE 57 DRIVERS HAVE 57 HGS ETR1 57 manufactures minimally invasive 57 Virulizin ® 57 Demonstrates Positive 57 MAY DIFFER 57 RELATIVELY HIGH SALES PER 57 Pattern scan 57 COULD DIFFER MATERIALLY FROM 57 TomKowalski NO 57 THAT HIS 57 IS HOPING TO 57 SNOW WILL CAUSE PRIMARILY 57 NS5B polymerase 57 elderly myelodysplastic syndromes 57 SEVERAL INCHES OF 57 PRESS RELEASE ARE FORWARD 57 BiovaxID TM 57 investigational pan BCR 57 Generx TM 57 candidate CRLX# 57 Schering Plough Remicade 57 candidates bavituximab 57 RANK Ligand inhibitor 57 MSBlast exploits flaw 57 Azedra 57 AS ARE CUSTOMARY 57 FITNESS FOR PURPOSE AND 57 Intravenous CP 57 Amigal TM 57 treat lupus renal 57 commercialize deforolimus 57 REJECTION OF 57 Capsulitis 57 OR OTHER EXPECTATIONS IMPLIED 57 SHALL NOT CONSTITUTE AN 57 tumor activated prodrug 57 COUNTRY FOR 57 paclitaxel Taxol ® 57 HCV protease inhibitor 57 Gorzno Poland 57 muscarinic receptor agonists 57 Phenoptin 57 nasal calcitonin product 57 non nucleoside HCV 57 THE CALL WARRANTS 57 TO MOVE INTO 57 candidates Augment ™ 57 COMPANIES FUTURE CAPITAL REQUIREMENTS 57 ThermoDox R 57 TO ARRANGE SHIPPING 57 Pegloticase 57 STATEMENTS RELATING TO 57 molecular chaperone regulation 57 arsenic trioxide injection 57 Initiates Clinical Trial 57 JACKSON HAS ISSUED 57 BELIEFS PLANS EXPECTATIONS OR 57 CEQ# 57 thetreatment 57 Oracea TM 57 HGS ETR2 57 humanized anti 57 FORWARD LOOKING INFORMATION WITHIN 57 use outsourced multilingual 57 FOR QUESTIONS ABOUT 57 PARIS HILTON HILTON 57 TKB# 57 Allovectin 7 57 INTENTIONS CONTAINED IN 57 Sister Joely Richardson 57 Evoltra ® 57 FUNDING AS WELL AS 57 plus dacarbazine 57 mGluR2 positive 57 octreotide implant 57 treat chronic sinusitis 57 opioid naive 57 phase IIb trial 57 gastrointestinal stromal 57 GOING OVERBOARD 57 TFChem licenses 57 Initiates Phase 57 Annamycin 57 Sudhir Agrawal D.Phil 57 Panzem NCD 57 Remember comment moderation 57 THE PROVINCIAL GOVERNMENT 57 2hours #mins #.#secs M 57 IPG PHOTONICS 57 MOST RECENTLY FILED ANNUAL 57 WEBSITE OR THE 57 metastatic sarcomas 57 THAT BROUGHT 57 Mylan Receives Approval 57 PURCHASE LETTER OF TRANSMITTAL 57 ACTEMRA TM 57 ® bortezomib 57 IRX 2 57 By Stacy Wolford 57 THE FACT THAT HE 57 AND VARIOUS 57 Cialis Generic Viagra Cialis 57 Nanobody 57 oral JAK#/JAK# inhibitor 57 TACI Ig 57 Disease IBD 57 By Neil Osterweil 57 R sorafenib tablets 57 RECORD CAN COMPLETELY 57 registered trademark Reg 57 XL# XL# XL# 57 data management Clintrial 57 signal detection CTSD 57 Vicinium TM 57 Novel Oral 57 ARE FOUND 57 TOTTENHAM MANAGER HARRY REDKNAPP 57 AKIP ™ 57 commercializes innovative biopharmaceuticals 57 ACTUAL RESULTS MIGHT DIFFER 57 RESULTS INDICATED OR IMPLIED 57 OF ORIGINALITY ACCURACY TIMELINESS 57 THE INVESTMENT BANKING 57 hyperplasia BPH 57 CAN BE EXPECTED NEAR 57 unique alkylating agent 57 earaches sprains cuts 57 MediGene focuses 57 THOUGHTS EXPRESSED HEREIN WITHOUT 57 womens cialis pfizer cialis 57 NEW COMMUNITY WEBSITES 57 metaglidasen 57 IF YOU HEAR THUNDER 57 oral Azacitidine 57 Carfilzomib 57 inflammation autoimmune diseases 57 ospemifene 57 MTP inhibitor 57 METHODOLOGIES ARE AVAILABLE FROM 57 label Lipofen R 57 THE RELEASE WHICH 57 candidate TNFerade biologic 57 SNT MC# 57 ENGLAND RECALL 57 R lenalidomide 57 Hsp# Inhibitor 57 Nasdaq AEGR 57 monoclonal antibody conjugated 57 Aurexis 57 VERANTWORTLICH 57 OTHER FACTORS THAT CAUSE 57 Oral Calcitonin 57 IN THEIR ENTIRETY BECAUSE 57 PROVES THAT 57 IS FOR INFORMATIONAL 57 Voreloxin 57 MGN# 57 SAYS THERE 'S 57 TO HELP THEM 57 FINANCIAL RISK IN 57 ZEVALIN ® 57 acute peripheral arterial 57 non nucleoside inhibitor 57 relapsed refractory multiple myeloma 57 PEG PAL 57 ARE ONLY PREDICTIONS 57 THE FOOD RETAIL 57 g r 57 ¢ ÃÆ'à † â 57 GATTEX TM 57 ACCOUNT OF 57 rNAPc2 57 Begins Dosing 57 Phase III multicenter 57 RELIANCE UPON ANY FORWARD 57 commercialize minimally invasive 57 anti VEGF aptamer 57 ARE AMONG THE 57 cancer therapeutics Adherex 57 CARL C. ICAHN 57 multiple sclerosis rheumatoid arthritis 57 IN SCOTTSBLUFF 57 IS DESCRIBED AS 57 THE OPTION MAY 57 THE SHURA COUNCIL 57 fungal infections malaria tuberculosis 57 proprietary BiTE ® 57 BY GEOFF KOHL 57 CIRCUMSTANCES AFTER THE 57 INVESTORS ARE CAUTIONED NOT 57 RECEIVE AN E MAIL 57 RELATIVELY GOOD PERFORMANCE DETECTED 57 plus Copegus R 57 THE NATIONAL HURRICANE 57 Coadministration 57 #.# LME Zinc [001] 57 news.de ein Presseportal der 57 trastuzumab Herceptin R 57 REMOXY POSIDUR ELADUR 57 docetaxel Taxotere ® 57 REDUCED DEMAND FOR 57 SHOULD READ CAREFULLY 57 comparing alemtuzumab 57 Ofatumumab 57 STATEMENTS CONTAINING FORWARD LOOKING 57 ionotropic glutamate receptor antagonists 57 UNITED STATES SECURITIES LAWS 57 developing KL4 surfactant 57 particularly SANCTURA XR 57 RHF Seven Summits Strategic 57 AND OTHER RISKS DETAILED 57 Nexavar ® 57 mertansine 57 Nventa proprietary CoVal 57 Perflubutane Polymer Microspheres 57 ALONG WITH OTHER 57 HOW MUCH HAS 57 zileuton injection 57 Kuvan R 57 HIGHLIGHTING THE 57 Ocrelizumab 57 TNFerade TM 57 OF NATIONAL REVIEW 57 BY JAMES MCNAIR 57 PRESS RELEASE AND ORAL 57 Cutaneous T 57 AFTER FATAL 57 Vascular Disrupting Agent 57 ASONEP TM 57 ularitide 57 THAT ARE PRECEDED BY 57 CSV short 57 immunotherapeutic approaches 56 diets Nevius 56 included exfoliative dermatitis 56 THESE DOCUMENTS AND OTHER 56 psoriasis rheumatoid arthritis 56 oxypurinol 56 IgG1 monoclonal antibody 56 Firdapse TM amifampridine phosphate 56 Hematide ™ 56 include VALSTAR TM 56 Aerosurf 56 About Positron Positron 56 metastatic pancreatic 56 ketolide antibiotic 56 Allovectin 7 R 56 CEO www.squeezetrigger.com +#-#-#-# 56 rusalatide acetate 56 WILL FOCUS ON 56 WAS BUT DEV 56 TomKowalski FELLAS 56 alfa 2a 56 ONYX PHARMACEUTICALS 56 Application MAA 56 Ceflatonin 56 compound INCB# 56 LOMUCIN TM 56 sunitinib Sutent ® 56 PEGINTRON REBETOL combination 56 relapsed leukemia 56 Presents Positive 56 EMD # 56 Exherin TM 56 Zalypsis 56 THE MATERIALS AND 56 Epratuzumab 56 EGFr humanized monoclonal antibody 56 Phase III Clinical Trial 56 CONTRIBUTE TO THE 56 SEES CONTINUED DOWNWARD MOMENTUM 56 Fx #A 56 IN PATIENTS WITH 56 produces potent VLP 56 Solazed ™ 56 TIGERS NEWS 56 PREMIERSHIP CHELSEA v 56 Madrid Bradley Klapper 56 PERPETUAL ENERGY INC. 56 Perifosine 56 multicenter Phase III 56 albiglutide 56 systemic immunosuppressive drugs 56 OCCURRENCE OF UNANTICIPATED EVENTS 56 dextromethorphan quinidine 56 Penguin NF P 56 carcinoma mCRC 56 trastuzumab DM1 T DM1 56 StaphVAX R 56 hepatitis C HCV 56 Submits NDA 56 SUBSCRIBE TO OUR RSS 56 ESTIMATES VARIATIONS OF SUCH 56 immunologic diseases 56 Cerebral Amyloid Angiopathy 56 Pruvel ™ prulifloxacin 56 Tanespimycin 56 tezampanel NGX# 56 investigational pharmacologically unique 56 HGS# 56 BRIM2 56 Ridaforolimus 56 KRN# 56 mGluR4 mGluR2 mGluR5 56 GED aPC 56 NEWLY DISCOVERED ORE BODIES 56 Metastatic Melanoma 56 dacetuzumab SGN 56 WLK appears 56 AND DESTRUCTIVE WINDS IN 56 Staff Writer jschramm@minotdailynews.com 56 Acura Buick Cadillac 56 cutaneous T cell 56 Oral Fingolimod 56 WHO LIVED 56 BY SUCH STATEMENTS 56 CAN CAUSE 56 Initiates Phase III 56 Solzira ™ 56 GATTEX ® 56 JAK2 inhibitor 56 € žÂ ¢ ÃÆ'à 56 CONTROL INCLUDING BUT NOT 56 approved incretin mimetic 56 Humanized Anti 56 Mutlaq Mahmoud 56 AKT inhibitor 56 SHOULD USE 56 trading house.net AG 56 IMC A# 56 % #F# #v.jsn 56 EGFR expressing metastatic colorectal 56 BELIEFS PLANS EXPECTATIONS AND 56 subcutaneous formulation 56 THAT COULD BE 56 Testosterone MDTS ® 56 Advanced Renal Cell 56 AND CONDITIONS TO 56 dirucotide MBP# 56 cell lymphoma CTCL 56 GUESS ALL JENS FRIENDS 56 post herpetic neuralgia PHN 56 THAT INCLUDE SUCH WORDS 56 midstage studies 56 ANY MATERIALS OR 56 sunitinib malate 56 THE COMPANY TO BE 56 DRUG DISCOVERY 56 CURRENT ESTIMATES AND MAY 56 Pivotal Phase III 56 BIOTECHNOLOGY INDUSTRY 56 NPC 1C 56 BY KEVIN LITTEN 56 AMONG OTHERS INVESTORS ARE 56 commercializing anti infective 56 THE PERSONAL PRODUCTS 56 NO PLANS TO 56 FUSILEV enhances 56 ® EBLY ® MASTERFOODS 56 RIGHT NOW IS 56 WITH HIGHER GUSTS 56 COMPARES TO THE UNDERLYING 56 FROM SEVERE THUNDERSTORMS 56 endoscopic autofluorescence imaging 56 OMNARIS HFA 56 SNOW OVER 56 Tyrima 56 Albuferon TM 56 Onalta 56 cystic fibrosis inflammation autoimmune 56 SUCCEED trial 56 acne impetigo 56 Deforolimus 56 o h r 56 Hematology Molecular Pathology 56 intranasal vaccines derived 56 ARE PROVIDED ON 56 THIS MONTH DRAWING 56 Aurora kinase inhibitor 56 CYC# 56 DISPLACED BY 56 ongoing Phase IIIb 56 THAT TROPICAL STORM CONDITIONS 56 Paid Print Subscribers ONLY 56 MEMPHIS HAS ISSUED 56 Trofex TM 56 ALL SUCH REPRESENTATIONS AND 56 novel emulsion formulation 56 BEEN REGISTERED UNDER 56 PURPOSE OF ESTIMATING SHIPPING 56 SILVER AND ITS 56 diabetes mellitus autoimmune disorders 56 commercial bioproduction 56 elotuzumab 56 ovarian esophageal 56 IMPORTANT FACTORS THAT COULD 56 Investigational Treatment 56 Unit Dose Budesonide 56 CCX# B 56 AFFILIATES AGENTS AND LICENSORS 56 tolerability pharmacokinetics 56 ENTB